Achillion Pharmaceuticals (NASDAQ:ACHN) Receiving Somewhat Positive Media Coverage, Report Finds

Headlines about Achillion Pharmaceuticals (NASDAQ:ACHN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a news impact score of 0.10 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.8528125071643 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media stories that may have impacted Accern’s scoring:

Achillion Pharmaceuticals (NASDAQ ACHN) traded up $0.05 during midday trading on Friday, reaching $2.95. 1,633,800 shares of the company’s stock traded hands, compared to its average volume of 1,834,058. The company has a market capitalization of $407.37, a price-to-earnings ratio of -6.02 and a beta of 1.52. Achillion Pharmaceuticals has a 1 year low of $2.69 and a 1 year high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. During the same quarter in the prior year, the business earned ($0.15) earnings per share. analysts forecast that Achillion Pharmaceuticals will post -0.61 earnings per share for the current fiscal year.

A number of equities analysts have commented on the stock. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research note on Monday, November 13th. BidaskClub raised shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 21st. Finally, Leerink Swann reissued a “buy” rating and set a $5.00 price target on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $5.13.

In other Achillion Pharmaceuticals news, major shareholder & Johnson Johnson sold 18,367,346 shares of the stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $2.75, for a total transaction of $50,510,201.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 7.24% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Achillion Pharmaceuticals (NASDAQ:ACHN) Receiving Somewhat Positive Media Coverage, Report Finds” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Insider Buying and Selling by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply